Dutch cancer biotech LAVA Therapeutics files for a $100 million US IPO

LAVA Therapeutics, a Dutch Phase 1/2a biotech developing novel bispecific antibodies for cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.

The company is focused on developing a platform of novel bispecific antibodies engineereRead More